Novo Nordisk A/S is a Danish pharmaceutical company that specializes in the research and production of medicines for diabetes, obesity and other metabolic diseases. The company is among the world's leading manufacturers of insulin products. Novo Nordisk is part of the fund because the company improves the treatment of widespread chronic diseases through its medicines and research, contributing to healthcare worldwide.